Abstract
To clarify the mechanism of acquired CDDP resistance in ovarian cancer, we compared the microsatellite instability (MSI) by the amplification of 10 microsatellite loci and immunohistochemical detection of hMSH2 and hMLH1 expression between the primary resected tumours and the secondary resected residual tumours after 5 or 6 courses of CDDP-based chemotherapy in the 24 cases of ovarian cancer. Of the 24 primary resected tumours, 9 (37.5%) showed MSI (7 cases of MSI-L, 2 cases of MSI-H), while 15 (72.5%) were microsatellite stable tumours (MSS). The primary tumours also had MSI in the residual tumours after CDDP-based chemotherapy. However, all of the cases with MSS in the primary resected tumours exhibited MSI (2 cases were MSI-L, and 13 cases were MSI-H) in the residual tumours after CDDP-based chemotherapy (P < 0.001). Furthermore, 11 (73.3%) of these cases which changed from MSS to MSI also had a change in the expression of hMLH1 from positive to undetectable (P < 0.001). Our data suggest that tumour MSI changes during CDDP-based chemotherapy, and that the loss of hMLH1 expression is one of the factors that has the greatest effect on this transformation. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aebi S, Kurdi-Haider B and Howell SB (1996) Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087–3090
Allen HJ, DiCioccio RA and Hohmann P (2000) Microsatellite instability in ovarian, other pelvic carcinomas. Cancer Genet Cytogenet 117: 163–166
Anthoney DA, Mcllwrath AJ, Gallagher WM, Edlin AR and Brown R (1996) Microsatellite instability, apoptosis, loss of p53 function in drug-resistant tumor cells. Cancer Res 56: 1374–1381
Arzimanoglou II, Lallas T and Gilbert F (1996) Microsatellite instability differences between familial and sporadic ovarian cancers. Carcinogenesis 17: 1799–1804
Boland CR, Thibodeau SN and Hamilton SR (1998) A national cancer institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248–5257
Bunz F, Hwang PM and Vogelstein B (1999) Distribution of p53 in human cancer cells alters the response to therapeutic agents. J Clin Invest 104: 263–269
Codegoni AM, Bertoni F and Colella G (1999) Microsatellite instability and frameshift mutations in genes involved in cell cycle progression or apoptosis in ovarian cancer. Oncol Res 11: 297–301
de las Alas MM, Aebi S and Los G (1997) Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst 89: 1537–1541
D'Incalci M, Bunfanti M and Fiebig HH (1998) The antitumour activity of alkylating agents is not correlated with the levels of glutathione, glutathione transferase and O6 alkylguanine-DNA-alkyltransferase of human tumour xenografts. EORTC SPG and PAMM Groups. Eur J Cancer 34: 1749–1755
Fink D, Nebel S and Howell SB (1996) The role of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56: 3087–3090
Fink D, Nebel S and Howell SB (1998) The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumor cells. Br J Cancer 77: 703–708
Haas CJ, Diebold J and Hirschmann A (1999) Microsatellite analysis in serous tumors of the ovary. Int J Gynecol Pathol 18: 158–162
Hickey KP, Boyle KP and Jepps HM (1999) Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br J Cancer 80: 1803–1808
Karran P and Hampson R (1996) Genomic instability and tolerance to alkylating agents. Cancer Surv 28: 69–85
Kusaba H, Nakayama M and Wada M (1999) Association of 5' CpG demethylation and altered chromatine structure in the promoter region with transcriptional activation of the multidrug resistance 1 gene in human cancer cells. Eur J Biochem 262: 924–832
Leith CP, Kopeckey KJ and William CL (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94: 1086–1099
Mackay HJ, Cameron D, Rahilly M, Mackean MJ, Paul J, Kaye SB and Brown R (2000) Reduced MLH1 expression in breast tumours after primary chemotherapy predicts disease free survival. J Clin Oncol 18: 87–93
Mcguire WP, Hoskins WJ, Brady MF, Kugera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Engl J Med 334: 1–6
Muggia FM, Braly PS, Brady MF, Sutton G, Niemann TH, Lentz SL, Alvarez RD, Kucera PR and Small JM (2000) Phase III randomized study of cisplatin versus paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 18: 106–115
Nishimura T, Newkirk K and Cullen KJ (1996) Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 2: 1859–1865
Omura GA, Bundy BN, Berek JS, Curry S, Delgado G and Mortel R (1989) Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A gynecologic oncology group study. J Clin Oncol 7: 457–465
Ozols RF (1997) Update of the NCCN ovarian cancer practice guidelines. Oncology 11: 95–105
Pieretti M, Cavalier C and Conway PS (1995) Genetic alterations distinguish different types of ovarian cancer. Int J Cancer 64: 434–440
Plumb JA, Strathdee G, Sludden J, Kaye SB and Brown R (2000) Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60: 6039–6044
Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS and Howell SB (2000) Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. Clin Cancer Res 6: 1415–1421
Strathdee G, Mackean MJ and Brown R (1999) A role of methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335–2341
WHO handbook for Reporting Results of Cancer Treatment (1979) WHO offset publication No.48. World Health Organization: Geneva
Zheng M, Wang H and Yu B (1999) The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells. J Cancer Res Clin Oncol 125: 357–360
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Watanabe, Y., Koi, M., Hemmi, H. et al. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br J Cancer 85, 1064–1069 (2001). https://doi.org/10.1054/bjoc.2001.2037
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2037
Keywords
This article is cited by
-
Japan Society of Clinical Oncology provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors, cooperated by Japanese Society of Medical Oncology, First Edition
International Journal of Clinical Oncology (2020)
-
ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
British Journal of Cancer (2013)
-
MutS homologue hMSH5: role in cisplatin-induced DNA damage response
Molecular Cancer (2012)
-
Tailored treatment for ovarian cancer: are we there yet?
Nature Reviews Clinical Oncology (2010)
-
Fractionated irradiation induced radio-resistant esophageal cancer EC109 cells seem to be more sensitive to chemotherapeutic drugs
Journal of Experimental & Clinical Cancer Research (2009)